glucose, (beta-d)-isomer has been researched along with Cardiac Failure in 465 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (1.94) | 18.7374 |
| 1990's | 1 (0.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 85 (18.28) | 24.3611 |
| 2020's | 370 (79.57) | 2.80 |
| Authors | Studies |
|---|---|
| Epstein, JA; Feldman, AM; Rosenthal, N | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Hauske, S; Packer, M; Pocock, SJ; Zannad, F; Zeller, C | 1 |
| Anand, I; Anker, SD; Butler, J; Carson, P; Doehner, W; Ferreira, JP; Filippatos, G; Haass, M; Komajda, M; Miller, A; Packer, M; Pehrson, S; Pocock, SJ; Schnaidt, S; Schnee, JM; Teerlink, JR; Zannad, F; Zeller, C | 1 |
| Mendoza, VL; Punzalan, FER; Tumanan-Mendoza, BA | 1 |
| Hayashi, Y; Hsiao, YT; Ikegami, R; Katsuumi, G; Minamino, T; Nakao, M; Okuda, S; Shimizu, I; Soga, T; Suda, M; Yoshida, Y | 1 |
| Huynh, K | 3 |
| Achenbach, S; Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Ott, C; Schiffer, M; Schmieder, RE; Stabel, L | 1 |
| Karabulut, D; Karabulut, U; Keskin, K; Yiğit, E; Yiğit, Z | 1 |
| Aiwale, A; Ghag, S; Pawar, R; Trailokya, AA; Zalke, A; Zargar, AH | 1 |
| Bluhmki, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Lachin, JM; Ofstad, AP; Ohneberg, K; Salsali, A; Schmoor, C; Schumacher, M; Wanner, C; Zannad, F; Zinman, B | 1 |
| Slomski, A | 5 |
| Anker, SD; Butler, J; Sattar, N; Verma, S | 1 |
| Lo, KB; Mathew, RO; Rangaswami, J; Vaduganathan, M | 1 |
| Blair, HA | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 4 |
| Chan, YY; Chang, KC; Chang, SH; Hung, MJ; Lai, EC; Lin, SJ; Shao, SC | 1 |
| Abu-Assi, E; Amat-Santos, IJ; Blas, SG; Cruz-Gonzalez, I; de la Torre Hernandez, JM; Diez-Gil, JL; Gheorge, L; Ibáñez, B; Iñiguez-Romo, A; Lopez-Otero, D; Melendo-Viu, M; Muñoz-Garcí, AJ; Nombela-Franco, L; Raposeiras-Roubín, S; Romaguera, R; Sánchez-Luna, JP; Sánchez-Recalde, Á | 1 |
| García, Á; Gil-Rojas, Y; Lasalvia, P | 1 |
| Bartuś, S; Budaj, A; Dąbrowski, M; Drożdż, J; Gellert, R; Grąbczewska, Z; Grzelakowska, K; Jaguszewski, MJ; Jankowski, P; Kubica, A; Kubica, J; Legutko, J; Lesiak, M; Leszek, P; Małyszko, J; Michalski, P; Mitkowski, P; Navarese, EP; Nessler, J; Niezgoda, P; Pawlaczyk, K; Siller-Matula, J; Stolarek, W; Stompór, T; Wolnik, B | 1 |
| Borlaug, BA; Chandra, L; Chaudhry, SP; Chow, CH; Clemson, BS; Fong, M; Gordon, RA; Joseph, SM; Kanwar, MK; Khan, SS; Khariton, Y; Khumri, T; Kitzman, DW; Kosiborod, MN; Lamba, S; Lewis, GD; Malik, AO; Nassif, ME; Pursley, M; Ryan, JJ; Shah, SJ; Sharma, K; Siraj, ES; Tang, F; Umpierrez, G; Windsor, SL | 1 |
| Hamaoka, T; Hirai, T; Inoue, O; Kato, T; Kawashiri, MA; Mukai, Y; Murai, H; Sakata, K; Sugimoto, H; Takamura, M; Takashima, S; Takata, S; Usui, S | 1 |
| Borlaug, BA; Burkhoff, D; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Videbæk, L | 1 |
| Anand, IS; Berg, DD; Chopra, V; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Langkilde, AM; Lindholm, D; McMurray, JJV; Morrow, DA; Nicolau, JC; O'Meara, E; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Welsh, P | 1 |
| Brand, SB; Kansal, AR; Koitka-Weber, A; Kuti, E; Pfarr, E; Reifsnider, OS; Stargardter, M; Ustyugova, A; Wang, C; Wanner, C | 1 |
| Achenbach, S; Bosch, A; Jung, S; Kannenkeril, D; Kolwelter, J; Ott, C; Pietschner, R; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Giannakoulas, G; Kotsa, K; Koufakis, T; Zebekakis, P | 1 |
| Bengtsson, O; Böhm, M; Butt, JH; de Boer, RA; Desai, AS; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Anker, SD; Böhm, M; Brueckmann, M; Butler, J; Chopra, VK; Filippatos, G; Jamal Siddiqi, T; Januzzi, JL; Kaul, S; Packer, M; Pedro Ferreira, J; Peil, B; Piña, IL; Pocock, SJ; Ponikowski, P; Senni, M; Shah, SJ; Vedin, O; Verma, S; Zannad, F | 1 |
| Egocheaga, I; Escobar, C; Obaya, JC; Pallarés, V | 2 |
| Adamson, C; Bengtsson, O; Butt, JH; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lindholm, D; Maria Langkilde, A; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Lim, GB | 3 |
| Barbancho, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Lara, JP; López-Carmona, MD; López-Sampalo, A; Millán-Gómez, M; Osuna-Sánchez, J; Pérez-Belmonte, LM; Ricci, M; Sanz-Cánovas, J | 1 |
| Echouffo-Tcheugui, JB; Lewsey, SC; Weiss, RG | 1 |
| Chen, QY; Guan, X; Jiang, YN; Lai, TF; Li, L; Ren, FF; Xie, ZY | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Dhingra, NK; Ferreira, JP; Filippatos, G; Januzzi, JL; Lam, CSP; Nordaby, M; Packer, M; Peil, B; Pocock, SJ; Sattar, N; Verma, S; Zannad, F | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Packer, M; Pocock, SJ; Schnee, J; Zannad, F; Zeller, C | 1 |
| Binder, H; Daiber, A; Gori, T; Jünger, C; Koeck, T; Lackner, KJ; Münzel, T; Prochaska, JH; Rapp, S; Schulz, A; Wild, PS | 1 |
| Anand, IS; Bengtsson, O; Desai, AS; Diez, M; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Nicolau, JC; O'Meara, E; Ogunniyi, MO; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Bates, ER | 1 |
| Anker, SD; Butler, J; Ferreira, JP; Filippatos, G; Pocock, SJ; Siddiqi, TJ; Zannad, F | 1 |
| Packer, M; Zannad, F | 2 |
| de Sousa, C; Pinto, FJ | 1 |
| de Boer, RA; Docherty, KF; Hammarstedt, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Ismail, TF; Pooni, RS | 1 |
| Bengtsson, O; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Simpson, J; Sjöstrand, M; Solomon, SD | 1 |
| Artola Arita, V; Rienstra, M; Van Veldhuisen, DJ | 1 |
| Badimón, JJ; Requena-Ibáñez, JA; Rodriguez-Cordero, A; Santos-Gallego, CG; Vargas-Delgado, AP | 1 |
| Jardine, MJ; O'Hara, DV | 1 |
| Gómez-Huelgas, R; Lara, JP; Miramontes-González, JP; Osuna-Sánchez, J; Pérez-Belmonte, LM | 1 |
| Balcı, C; Ismayilov, R | 1 |
| Balogh, DB; Barczi, A; Fekete, A; Fintha, A; Hodrea, J; Molnar, A; Saeed, A; Szabo, AJ; Wagner, LJ | 1 |
| Akasaka, H; Fujio, Y; Fukuda, M; Iwakura, K; Kamide, K; Nakatani, S; Ogihara, T; Okamura, A; Rakugi, H; Shintani, A; Sugimoto, K; Takiuchi, S; Taniuchi, S; Yamamoto, K | 1 |
| Andersen, CF; Gustafsson, F; Højlund, K; Jensen, J; Kistorp, C; Køber, L; Larsen, JH; Møller, JE; Omar, M; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Angermann, CE; Biegus, J; Blatchford, JP; Borleffs, CJW; Brueckmann, M; Collins, SP; Comin-Colet, J; Ferreira, JP; Fu, M; Janssens, SP; Kiss, RG; Kosiborod, M; Ma, C; Mentz, RJ; Nassif, ME; Ponikowski, P; Psotka, MA; Sakata, Y; Salsali, A; Schirmer, H; Schou, M; Schulze, PC; Spinarova, L; Teerlink, JR; Tromp, J; Volterrani, M; Voors, AA; Wranicz, JK; Zeymer, U; Zieroth, S | 1 |
| Zheng, H | 1 |
| Kiyakbaev, G; Kokhan, E; Medovchshikov, V | 1 |
| Seki, H; Watanabe, H; Yorozu, T | 1 |
| Frullone, S; Gambardella, J; Lombardi, A; Macina, G; Mone, P; Morgante, M; Pansini, A; Santulli, G | 2 |
| Miller, WL | 1 |
| Chen, S; Coronel, R; Hollmann, MW; Weber, NC; Zuurbier, CJ | 1 |
| Anker, SD; Fitchett, DH; Inzucchi, SE; Lauer, S; Pernille Ofstad, A; Sander, LE; Vedin, O; Verma, S; Wanner, C; Yaggi, HK; Zinman, B | 1 |
| Anker, SD; Butler, J; Ferreira, JP; Filippatos, G; Januzzi, JL; Packer, M; Pocock, S; Schueler, E; Steubl, D; Zannad, F; Zeller, C | 1 |
| Bers, DM; Bossuyt, J; Habibi, NR; Hegyi, B; Mira Hernandez, J; Shen, EY | 1 |
| Angermann, CE; Biegus, J; Blatchford, JP; Brueckmann, M; Collins, SP; Comin-Colet, J; Ferreira, JP; Kosiborod, MN; Mentz, RJ; Nassif, ME; Ponikowski, P; Psotka, MA; Salsali, A; Teerlink, JR; Tromp, J; Voors, AA | 1 |
| Larkin, HD | 1 |
| Ebell, MH | 1 |
| Colivicchi, F; Gronda, E; Zuccalà, G | 1 |
| Adamson, C; Bengtsson, O; Damman, K; de Boer, RA; Docherty, KF; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vaduganathan, M; Verma, S | 1 |
| Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC | 1 |
| Stiefelhagen, P | 1 |
| Belohlávek, J; Bengtsson, O; Butt, JH; Chiang, CE; Dewan, P; Docherty, KF; Drożdż, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Bengtsson, O; Boulton, DW; Docherty, KF; Greasley, PJ; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE | 1 |
| Aimo, A; Barison, A; Bayes-Genis, A; Emdin, M; Panichella, G; Passino, C; Senni, M | 1 |
| Aylward, P; Bhatt, DL; Cahn, A; Dalby, AJ; Dellborg, M; Dimulescu, D; Furtado, RHM; Gause-Nilsson, I; Goodrich, EL; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Oude Ophuis, AJM; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Ali, M; Andersen, CF; Ersbøll, MK; Faber, J; Forman, JL; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Larsen, JH; Møller, JE; Omar, M; Schou, M; Tuxen, C | 1 |
| Benson, L; Cosentino, F; Dahlström, U; Ferrannini, G; Lund, LH; McMurray, JJV; Mellbin, L; Savarese, G; Thorvaldsen, T | 1 |
| Facharztmagazine, R | 1 |
| Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Sumin, M; Udell, JA; Vedin, O; Zwiener, I | 1 |
| Fu, Z; Husain, M; Ilkayeva, O; Inzucchi, SE; Javaheri, A; Jones, P; Kosiborod, MN; Kwee, LC; Lanfear, DE; Margulies, KB; McGuire, DK; Mentz, RJ; Nassif, ME; Newgard, CB; Pitt, B; Scirica, BM; Selvaraj, S; Shah, SH; Windsor, SL | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Packer, M; Pocock, SJ; Siddiqi, TJ; Zannad, F; Zeller, C | 1 |
| Ananicheva, N; Andreev, D; Bogdanova, A; Charaya, K; Dyachuk, I; Kuzub, A; Mesitskaya, D; Poltavskaya, M; Shchekochikhin, D; Tarasenko, S | 1 |
| Bhattacharyya, D; Dhumale, S; Kar, A | 1 |
| Iliodromitis, EK; Triposkiadis, FK; Xanthopoulos, A | 1 |
| Amato, J | 1 |
| Greene, T; Heerspink, HJL; Inker, L | 1 |
| Anker, SD; Butler, J; Packer, M | 1 |
| Cosentino, F; Dhingra, NK; Pandey, AK; Verma, S | 1 |
| Anker, SD; Butler, J; Ferreira, JP; Filipattos, G; Kraus, BJ; Packer, M; Pocock, SJ; Ritter, I; Schüler, E; Zannad, F | 1 |
| Hao, Z; Zhang, Y | 2 |
| Fujiki, S; Imai, T; Inomata, T; Kashimura, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Shimabukuro, M; Suzuki, M; Tanaka, A; Uehara, H | 1 |
| Nishikawa, Y; Supakul, S; Takase, T; Teramura, M | 1 |
| Abdin, A; Anker, SD; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Gollop, ND; Iwata, T; Mahfoud, F; Packer, M; Pocock, SJ; Ponikowski, P; Wanner, C; Zannad, F | 1 |
| Sauer, AJ | 1 |
| Aimo, A; Bayes-Genis, A; Lupón, J | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F | 1 |
| Krittayaphong, R; Permsuwan, U | 2 |
| Almengló, C; Durán, D; Eiras, S; Fernández, ÁL; Flores-Arias, MT; Fu, X; González-Juanatey, JR; Martínez-Cereijo, JM; Rodríguez-Mañero, M; Viñuela, JE | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Goodrich, EL; Leiter, LA; McGuire, DK; Mosenzon, O; Oyama, K; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Dural, İE; Ersoy, İ; Sarı, A | 1 |
| AlHummiany, B; Allwood-Spiers, S; Berry, C; Brooksbank, KJM; Campbell, RT; Chong, V; Coyle, L; Docherty, KF; Dreisbach, JG; Gillis, KA; Hall Barrientos, P; Jhund, PS; Kuehn, B; Labinjoh, C; Lang, NN; Lee, MMY; Lennie, V; Mangion, K; Mark, PB; McConnachie, A; McMurray, JJV; Murphy, CL; Petrie, CJ; Petrie, JR; Petrie, MC; Radjenovic, A; Roditi, G; Sattar, N; Sharma, K; Sourbron, S; Speirits, IA; Thompson, J; Welsh, P; Wetherall, K; Woodward, R; Wright, A | 1 |
| Calò, L; Cicogna, F; Ferrari, I; Monzo, L; Tota, C | 1 |
| Bengtsson, O; Biering-Sørensen, T; Butt, JH; DeFilippis, EM; Dewan, P; Docherty, KF; Fiuzat, M; Jhund, PS; Johansen, ND; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD; Vaduganathan, M | 1 |
| Gu, N; Liang, B | 2 |
| Frantz, S; Morbach, C; Nitschmann, S | 1 |
| Chen, M; Cheng, J; Ding, R; Gu, JF; Huang, JL; Tang, TJ; Wang, L; Wang, X; Zhou, P; Zuo, MY | 1 |
| Biegus, J; Ponikowski, P | 1 |
| MacDonald, TM; Mackenzie, IS | 1 |
| Bengtsson, O; De Boer, RA; Docherty, KF; Hammarstedt, A; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Little, DJ; Martinez, FA; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S; Welsh, P | 1 |
| Faber, J; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C | 1 |
| Nakajima, T; Node, K; Oyama, JI; Shimizu, T; Shiraki, A; Yokota, T | 1 |
| Ferry, A | 1 |
| Al Habeeb, W; Alcocer-Gamba, MA; Bachus, E; Belohlavek, J; Borleffs, CJW; Cabrera Honorio, JW; Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Dobreanu, D; Drozdz, J; Fang, JC; Han, Y; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Merkely, B; O'Meara, E; Petersson, M; Pham, VN; Saraiva, JFK; Shah, SJ; Solomon, SD; Tereshchenko, SN; Thierer, J; Vaduganathan, M; Vardeny, O; Verma, S; Wilderäng, U; Zaozerska, N | 1 |
| Bachus, E; Belohlávek, J; Butt, JH; Chiang, CE; Claggett, BL; de Boer, RA; Desai, AS; Drożdż, J; Hernandez, AF; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Lindholm, D; Maria Langkilde, A; Martinez, F; McMurray, JJV; Merkely, B; Petersson, M; Saraiva, JFK; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O; Wilderäng, U | 1 |
| Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Hernandez, AF; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Kulac, IJ; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Peikert, A; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O; Wilderäng, U | 1 |
| Bengtsson, O; Butt, JH; Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Docherty, KF; Gasparyan, SB; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kondo, T; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Petersson, M; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M | 1 |
| Anker, S; Butler, J; Harrington, J | 1 |
| Claggett, BL; Cunningham, JW; de Boer, RA; DeMets, D; Desai, AS; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Kulac, IJ; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McGrath, MM; McMurray, JJV; O'Meara, E; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Wilderäng, U | 1 |
| Capece, U; Cinti, F; Cocchi, C; Crea, F; D'Amario, D; Ferraro, PM; Giaccari, A; Giordano, A; Gugliandolo, S; Guzzardi, MA; Indovina, L; Iozzo, P; Leccisotti, L; Lorusso, M; Mezza, T; Sorice, GP | 1 |
| Meißner, T | 1 |
| Bachir, N; Boukabous, A; Terki, A; Zaoui, N | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Butler, J; Chopra, VK; Ferreira, JP; Filippatos, G; Giannetti, N; Iwata, T; Januzzi, JL; Kaul, S; Packer, M; Piña, IL; Pocock, SJ; Ponikowski, P; Rauch-Kröhnert, U; Senni, M; Shah, SJ; Siddiqi, TJ; Sumin, M; Verma, S; Zannad, F; Zhang, J | 1 |
| Chen, K; Liu, J; Qin, S; Qin, Y; Wang, C; Wu, X; Xiao, W; Yang, Y; Zhang, X | 1 |
| Fernández-Ruiz, I | 2 |
| Ji, Y; Sun, L; Wang, FF; Yan, XJ; Zhang, JL; Zhu, Y | 1 |
| Giri, S; Guha, A; Lanfear, DE; Ortiz, PA; Palaniyandi, SS; Pan, G; Roy, B; Thandavarayan, RA | 1 |
| Chen, F; Chen, K; Hwa, J; Jiang, K; Qian, J; Wang, D; Wang, H; Wu, Y; Xiang, Y; Xu, Y; Yang, B; Yu, Y; Zhou, C | 1 |
| Chang, R; Cui, B; Fan, Z; Hiram, R; Huang, C; Huang, H; Liu, T; Shi, S; Su, X; Tang, Y; Wu, G; Wu, J; Xiong, F; Yan, M; Zhang, W | 1 |
| Calabria, S; Cricelli, C; Dondi, L; Lapi, F; Maggioni, AP; Marconi, E; Martini, N; Medea, G; Parretti, D; Pedrini, A; Piccinni, C; Ronconi, G | 1 |
| Claggett, BL; de Boer, RA; Desai, AS; Hegde, SM; Hernandez, AF; Inzucchi, SE; Jhund, P; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M | 1 |
| Fudim, M; Van Spall, HGC | 1 |
| Ma, H; Ma, Y | 1 |
| Prázný, M | 1 |
| Adams, V; Augstein, A; Barthel, P; Goto, K; Jannasch, A; Labeit, S; Langner, E; Linke, A; Mangner, N; Männel, A; Schauer, A; Winzer, EB | 1 |
| Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE | 1 |
| Angermann, CE; Biegus, J; Blatchford, JP; Brueckmann, M; Collins, SP; Ferreira, JP; Kosiborod, MN; Nassif, ME; Ponikowski, P; Psotka, MA; Salsali, A; Teerlink, JR; Tromp, J; Voors, AA | 1 |
| Ageev, FT; Ametov, AS; Antsiferov, MB; Arutyunov, GP; Cherkashin, DV; Fomin, IV; Galstyan, GR; Galyavich, AS; Gilyarevskiy, SR; Glezer, MG; Ilyin, MV; Khalimov, IS; Khasanov, NR; Lebedeva, AI; Lopatin, YM; Nedogoda, SM; Salukhov, VV; Tarlovskaya, EI; Tereshchenko, SN; Villevalde, SV; Vinogradova, NG; Yakushin, SS; Zhirov, IV | 1 |
| Claggett, BL; de Boer, RA; Desai, AS; Docherty, K; Fang, J; Hernandez, AF; Inzucchi, SE; Jhund, P; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, F; Mc Causland, FR; McGrath, MM; McMurray, JJV; Petersson, M; Saraiva, JFK; Shah, SJ; Solomon, SD; Vaduganathan, M; Verma, S | 1 |
| Gutmann, C; Mayr, M; Zelniker, TA | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Dhingra, NK; Filippatos, G; Januzzi, JL; Lam, CSP; Nordaby, M; Packer, M; Pedro Ferreira, J; Pfarr, E; Pocock, SJ; Sattar, N; Verma, S; Zannad, F | 1 |
| Güzel, T; İnci, Ü | 1 |
| Colombo, PC; Mebazaa, A; Solal, AC | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Butler, J; Choi, DJ; Chopra, V; Chuquiure, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; González-Juanatey, JR; Iwata, T; Janssens, S; Januzzi, JL; Merkely, B; Nicholls, SJ; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Rocca, HPB; Schnee, JM; Senni, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Usman, MS; Verma, S; Vinereanu, D; Zannad, F; Zhang, J | 1 |
| Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Drozdz, J; Fang, JC; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; O'Meara, E; Petersson, M; Solomon, SD; Vaduganathan, M; Vardeny, O; Zieroth, S | 1 |
| Adeyeye, E; Khong, TK | 1 |
| Bayes-Genis, A; Núñez, J | 1 |
| Beernink, JM; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Laverman, GD; McMurray, JJV; Persson, F; Rossing, P; Sjöström, CD; Toto, RD; Wheeler, DC | 1 |
| Al-Mubarak, AA; Bomer, N; Damman, K; Heerspink, HJL; Schomburg, L; van der Meer, P; van Veldhuisen, DJ; Voors, AA; Weening, EH | 1 |
| Bég, SA; Dar, MS; Kaspers, S; Marx, N; Mattheus, M; Ofstad, AP; Wanner, C | 1 |
| Borleffs, CJW; Claggett, BL; de Boer, RA; Desai, AS; Dobreanu, D; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jering, KS; Jhund, PS; Kondo, T; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Solomon, SD; Vaduganathan, M; Vinh, PN | 1 |
| Melenovsky, V; Monzo, L | 1 |
| Kosiborod, MN; Selvaraj, S; Shah, SH | 1 |
| Butt, JH; McMurray, JJV; Solomon, SD | 1 |
| Angermann, CE; Biegus, J; Blatchford, JP; Collier, TJ; Collins, SP; Ferreira, JP; Gregson, J; Kosiborod, M; Nassif, ME; Pocock, SJ; Ponikowski, P; Psotka, MA; Teerlink, JR; Tromp, J; Voors, AA; Zeller, C | 1 |
| Al Thani, NA; Hasan, M; Yalcin, HC | 1 |
| Altiok, E; Böhm, M; Grebe, J; Keszei, AP; Korbinian Hartmann, NU; Lehrke, M; Marx, N; Rau, M; Thiele, K | 1 |
| Wiley, T; Williams, L | 1 |
| Desai, RJ; Everett, BM; Fu, EL; Levin, R; Patorno, E; Schneeweiss, S; Solomon, SD; Vaduganathan, M | 1 |
| Bachus, E; Booth, D; Chen, J; Comin-Colet, J; Davis, JA; De Boer, RA; McEwan, P; McMurray, JJV; Solomon, SD | 1 |
| Anand, I; Berg, DD; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Osmanska, J; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Choi, YJ; Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lim, J; Na, JO; Park, JB; Rhee, TM | 1 |
| Lam-Chung, CE | 1 |
| Greenberg, B; Park, JJ | 1 |
| Mukherjee, D | 1 |
| Ohshiro, Y | 1 |
| Ishii, H; Iso, T; Kawakami, R; Kurabayashi, M; Matsui, H; Matsui, M; Yokoyama, T | 1 |
| Macari, S; Zannad, F | 1 |
| Boulton, DW; Cain, V; Dekkers, CCJ; Greasley, PJ; Heerspink, HJL; Sjöström, CD | 1 |
| Feng, B; Ma, X; Sun, K; Xu, G; Zhang, N; Zhou, Y | 1 |
| Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Filippatos, GS; George, J; Jamal, W; Kimura, K; Packer, M; Salsali, A; Schnee, J; Zannad, F; Zeller, C | 2 |
| Austin, B; Drazner, MH; Fong, MW; Givertz, MM; Gordon, RA; Husain, M; Inzucchi, SE; Jermyn, R; Katz, SD; Khariton, Y; Kosiborod, M; Lamba, S; Lanfear, DE; LaRue, SJ; Lindenfeld, J; Malone, M; Margulies, K; McGuire, DK; Mentz, RJ; Mutharasan, RK; Nassif, ME; Pitt, B; Pursley, M; Scirica, BM; Tang, F; Umpierrez, G; Windsor, SL | 1 |
| Fang, JC | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Packer, M | 3 |
| Kato, ET; Sabatine, MS; Wiviott, SD | 1 |
| Elghazaly, H; Hajiev, S; Singh, P | 1 |
| Bhatt, DL; Braunwald, E; Verma, S | 1 |
| Butler, J; Vaduganathan, M | 1 |
| Bengtsson, O; Chiang, CE; DeMets, DL; Dutkiewicz-Piasecka, M; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Felker, GM | 1 |
| Bengtsson, O; DeMets, DL; Diez, M; Docherty, KF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; Niklasson, A; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Fukushima, A; Furihata, T; Kakutani, N; Katayama, T; Kinugawa, S; Maekawa, S; Matsumoto, J; Nakano, I; Nambu, H; Obata, Y; Saito, A; Shirakawa, R; Takada, S; Yamanashi, K; Yokota, T | 1 |
| Collins, SP; Tromp, J | 1 |
| DeVore, AD; Ezekowitz, JA; Felker, GM; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Mahaffey, KW; Sharma, A; Udell, JA; Wu, J | 1 |
| Hirose, M; Ibi, M; Ishida, N; Matsushita, N; Morino, Y; Saito, M; Sawa, Y; Taira, E | 1 |
| Ambrosio, G; Anker, S; Bauersachs, J; Chioncel, O; Coats, AJS; Cosentino, F; De Boer, RA; Filippatos, G; Hill, L; Huelsmann, M; Jhund, PS; Komajda, M; Lopatin, Y; Lund, LH; Lyon, A; Metra, M; Mullens, W; Petrie, MC; Piepoli, M; Polovina, MM; Ponikowski, P; Rosano, GMC; Sari, I; Seferović, J; Seferović, PM; Thum, T; Volterrani, M | 1 |
| Harrison, SL; Lane, DA; Lip, GYH | 1 |
| Anker, SD; Böhm, M; Brueckmann, M; Fitchett, D; George, JT; Inzucchi, SE; Marx, N; Mattheus, M; Ofstad, AP; Slawik, J; Verma, S; Wanner, C; Zinman, B | 1 |
| Verma, S | 1 |
| Docherty, KF; Jhund, PS; McMurray, JJV; Solomon, SD | 1 |
| Ablasser, K; Alber, H; Berger, R; Kaulfersch, C; Kolesnik, E; Leitner, K; Lichtenauer, M; Mader, A; Moertl, D; Oulhaj, A; Pferschy, PN; Reiter, C; Rieder, T; Saely, CH; Sailer, S; Siller-Matula, J; Sourij, H; Tripolt, NJ; Verheyen, N; von Lewinski, D; Weidinger, F; Zechner, PM | 1 |
| Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H | 2 |
| Beusekamp, JC; Boorsma, EM; Damman, K; Elvan, A; Heerspink, HJL; Smilde, TDJ; Swart, HP; van Eck, JWM; Voors, AA | 1 |
| Cauchon, M; Dussault, C; Huard, G; Lanthier, L; Plourde, MÉ | 1 |
| Braam, B; Byrne, NJ; Darwesh, AM; Dyck, JRB; El-Kadi, AOS; Ferdaoussi, M; Jahng, JWS; Levasseur, JL; Light, PE; Maayah, ZH; Matsumura, N; Parajuli, N; Seubert, JM; Sweeney, G; Takahara, S; Verma, S; Vos, D; Young, ME | 1 |
| Advani, A; Batchu, SN; Connelly, KA; Desjardins, JF; Gilbert, RE; Kabir, G; Nghiem, L; Thai, K; Visram, A; Yerra, VG; Zhang, Y | 1 |
| Sullivan, K; Van Spall, HGC | 1 |
| Maier, LS; Mustroph, J; Trum, M; Wagner, S | 1 |
| de Boer, RA; Keefe, D; Kozlovski, P; Núñez, J; Proot, P; Wang, Y | 1 |
| Groenewegen, A; Rutten, FH | 1 |
| Casella, R; Casiraghi, C; Cazzaniga, A; Colombo, G | 1 |
| Borghi, C; Cicero, AFG | 1 |
| Dau, NQ; Peled, H | 1 |
| Mehra, MR; Vieira, JL | 1 |
| Docherty, KF; Jhund, PS; McMurray, JJV | 1 |
| Gu, N; Liang, B; Zhao, YX | 1 |
| Arnott, C; Neal, B | 1 |
| Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Bengtsson, O; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S; Vinh, PN | 1 |
| Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B; Zwiener, I | 1 |
| Choy, AMJ; Donnan, PT; Fathi, A; Gandy, S; George, J; Houston, JG; Khan, F; Lang, CC; Mohan, M; Mordi, IR; Pearson, ER; Singh, JSS; Struthers, AD; Vickneson, K | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ishiyama, M; Ito, M; Moriwaki, K; Omori, T; Takeuchi, T | 1 |
| Altay, H; Cahn, A; Çavuşoğlu, Y; Celik, A; Demir, S; Kılıçaslan, B; Nalbantgil, S; Raz, I; Temizhan, A; Yıldırımtürk, Ö; Yılmaz, MB | 1 |
| Carballo, D; Carballo, S; Darbellay Farhoumand, P; Garin, N; Serratrice, J; Stirnemann, J | 1 |
| Ghosal, S; Sinha, B | 1 |
| Ferreira, JP; Fitchett, D; George, JT; Kraus, BJ; Lauer, S; Ofstad, AP; Rossignol, P; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A | 1 |
| Bagi, Z; Carrizzo, A; Ciccarelli, M; Falcão-Pires, I; Fülöp, GÁ; Hamdani, N; Herwig, M; Kolijn, D; Kovács, Á; Linthout, SV; Lódi, M; Maier, LS; Mügge, A; Pabel, S; Papp, Z; Reusch, PH; Sossalla, S; Tian, Y; Tschöpe, C; van Heerebeek, L; Vecchione, C; Zhazykbayeva, S | 1 |
| Ahmad, T; Bellumkonda, L; Butler, J; Collins, S; Cox, Z; Fleming, J; Griffin, M; Inzucchi, SE; Ivey-Miranda, J; Jacoby, D; Jeon, S; Mahoney, D; Maulion, C; Rao, VS; Riello, R; Siwakoti, K; Suda, N; Testani, JM; Turner, JM; Wilson, FP | 1 |
| Fitchett, DH; George, JT; Inzucchi, SE; Khunti, K; Mattheus, M; Ofstad, AP; Wanner, C; Zinman, B | 1 |
| Mareev, VY; Tsygankova, OV; Veretyuk, VV | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Chopra, VK; DeMets, DL; Dewan, P; Dukát, A; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkely, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vinh, PN | 1 |
| Kim, HJ; Kim, JJ; Seong, JM; Sohn, HS | 1 |
| Anker, SD; Böhm, M; Brueckmann, M; Fitchett, D; George, JT; Kaspers, S; Mahfoud, F; Mancia, G; Marx, N; Ofstad, AP; Wanner, C; Zinman, B; Zwiener, I | 1 |
| Costantino, S; Paneni, F; Sciarretta, S | 1 |
| Patel, AB; Verma, A; Waikar, SS | 1 |
| Bengtsson, O; Claggett, BL; Desai, AS; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjostrand, M; Solomon, SD | 1 |
| Gazewood, JD; Tingen, J | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Boulton, DW; Chopra, VK; de Boer, RA; DeMets, DL; Dewan, P; Docherty, KF; Dukát, A; Greasley, PJ; Howlett, JG; Inzucchi, SE; Jackson, AM; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Sabatine, MS; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S | 1 |
| Badimon, JJ; Garcia-Ropero, A; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; Santos-Gallego, CG; Sanz, J; Tunon, J; Vargas-Delgado, AP | 1 |
| Bergenheim, K; Böhm, M; Darlington, O; Docherty, KF; Jhund, PS; McEwan, P; McMurray, JJV; Petrie, MC; Qin, L | 1 |
| Raj, GM; Wyawahare, M | 1 |
| Bruun, NE; Brønd, JC; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Ahmad, T; Desai, NR | 1 |
| Basu, S; Hallow, KM; Yu, H | 1 |
| Lester, S; Van Klompenburg, E | 1 |
| Cowie, MR | 1 |
| Alenina, N; Bader, M; Crespo-Garcia, S; Dechend, R; Ebrahim, M; Golic, M; Grune, J; Haase, N; Herse, F; Heuser, A; Kintscher, U; Kräker, K; Luft, FC; Müller, DN; Reichhart, N; Strauß, O | 1 |
| Anand, IS; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Diez, M; Docherty, KF; Dukát, A; Ge, J; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Aschenbrenner, DS | 2 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Jarcho, JA | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Ofstad, AP; Packer, M; Pfarr, E; Pocock, SJ; Zannad, F | 1 |
| Anand, I; Bengtsson, O; Böhm, M; de Boer, RA; DeMets, DL; Desai, AS; Docherty, KF; Drozdz, J; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S | 1 |
| Katsiki, N; Kotsa, K; Kotsis, V | 1 |
| Cosentino, F; Savarese, G | 1 |
| De Caterina, R; Doria, V; Madonna, R; Minnucci, I; Pierdomenico, DS; Pucci, A | 1 |
| Anker, SD; Butler, J; Fonarow, GC; Handelsman, Y; Hernandez, AF; Khan, MS; Kosiborod, MN; McGuire, DK; McMurray, JJV; Rosenstock, J; Vaduganathan, M; Verma, S | 1 |
| Kosiborod, MN; McGuire, DK; Verma, S | 1 |
| George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC | 1 |
| Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD | 1 |
| Sotirakos, S | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Anand, IS; Bengtsson, O; Böhm, M; Chopra, V; de Boer, RA; Desai, AS; Docherty, KF; Ge, J; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkley, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Shou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K | 1 |
| Nangaku, M | 1 |
| Anand, I; Anker, SD; Brueckmann, M; Butler, J; Carson, P; Doehner, W; Ferreira, JP; Filippatos, G; Haass, M; Jamal, W; Komajda, M; Miller, A; Packer, M; Pehrson, S; Pocock, SJ; Schnaidt, S; Teerlink, JR; Zannad, F; Zeller, C | 1 |
| Bengtsson, O; DeMets, DL; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Penland, RC; Tang, W; Yu, H | 1 |
| Badimon, JJ; Garcia-Ropero, A; Santos-Gallego, CG | 1 |
| Brunton, S; Chilton, R | 1 |
| Cai, S; Connelly, K | 1 |
| Badimon, JJ; Flores-Umanzor, EJ; Fuster, V; Garcia-Ropero, A; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; San Antonio, R; Santos-Gallego, CG; Sanz, J; Vargas-Delgado, AP; Watanabe, S | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Haynes, R; Judge, PK | 1 |
| Panchapakesan, U; Pollock, C | 1 |
| Butler, J; Greene, SJ; Khan, MS | 1 |
| Bengtsson, O; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE | 1 |
| Anker, SD; Bocchi, EA; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Marx, N; Ofstad, AP; Packer, M; Perrone, SV; Pocock, SJ; Ponikowski, P; Schnaidt, S; Verma, S; Zannad, F | 1 |
| Deswal, A; Palaskas, NL | 1 |
| Abascal, VM; Atallah-Lajam, F; Badimon, JJ; Contreras, JP; Fergus, I; Fuster, V; Garcia-Ropero, A; Lala, A; Macaluso, F; Mancini, D; Moreno, PR; Pinney, S; Requena-Ibanez, JA; Rodriguez-Cordero, A; Roque, M; Sabatel-Perez, F; Santos-Gallego, CG; Sanz, J; Sartori, S; Tamler, R; Vargas-Delgado, AP; Varley, C; Zafar, MU | 1 |
| Beusekamp, JC; Boorsma, EM; Damman, K; Danser, AHJ; Figarska, SM; Heerspink, HJL; Ter Maaten, JM; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Zannad, F; Zeller, C | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Choi, DJ; Chopra, V; Chuquiure, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Schnaidt, S; Schnee, JM; Senni, M; Seronde, MF; Shahzeb Khan, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zhang, J | 1 |
| Ibrahim, NE; Januzzi, JL | 1 |
| Node, K; Tanaka, A | 2 |
| Khunti, K | 1 |
| Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Abraham, WT; Agostoni, P; Anker, SD; Brueckmann, M; Butler, J; Desai, AS; Filippatos, G; Fu, M; Gniot, J; Gullestad, L; Howlett, JG; Jamal, W; Krzysztof Wranicz, J; Lindenfeld, J; Nicholls, SJ; Nordaby, M; Peil, B; Ponikowski, P; Redon, J; Ritter, I; Salsali, A; Savarese, G; Schenkenberger, I; Silva-Cardoso, J; Störk, S; Ustyugova, A; Zeller, C | 1 |
| Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; de Boer, RA; Diez, M; Docherty, KF; Dukát, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Heerspink, HJL; Muskiet, MHA; van Raalte, DH | 1 |
| Bruun, NE; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Jensen, LT; Kistorp, C; Køber, L; Malik, ME; Møller, JE; Omar, M; Schou, M; Tuxen, C | 1 |
| Lang, NN; Lee, MM; Petrie, MC | 1 |
| Bengtsson, O; de Boer, RA; Desai, AS; Dewan, P; Docherty, KF; Drozdz, J; Hawkins, NM; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Martens, P; Mullens, W | 2 |
| Acharya, Y; Dahal, R; Mukherjee, D | 1 |
| Nabavizadeh, P; Steen, DL | 1 |
| Ali, M; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Möller, S; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, CD; Videbæk, L | 1 |
| Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Giannetti, N; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Packer, M; Peil, B; Piña, IL; Pocock, SJ; Ponikowski, P; Sattar, N; Vedin, O; Verma, S; Zannad, F; Zeller, C | 1 |
| Bauersachs, J | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Janssens, S; Packer, M; Pocock, SJ; Rocca, HB; Schnee, J; Tsutsui, H; Zannad, F; Zhang, J | 1 |
| Metra, M; Tomasoni, D | 1 |
| Kosiborod, M | 1 |
| Huang, J; Lin, X; Wang, S | 1 |
| Angoulvant, D; Fauchier, G; Fauchier, L | 1 |
| Bhattacharyya, D; Kar, A | 1 |
| Goswami, RM; Shanmuganathan, M | 1 |
| Esnault, VLM; Favre, G; Gérard, AO | 1 |
| Kumar, S; Sinha, S | 1 |
| Araújo, I; Cunha, GJL; Fonseca, C; Guerreiro, R; Henriques, C; Maltês, S; Presume, J; Rocha, BML; Rodrigues, C | 1 |
| Brodovicz, KG; Chung, WJ; Deruaz-Luyet, A; H-H Sheu, W; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Tan, EC; Yabe, D; Yasui, A | 1 |
| Bengtsson, O; Böhm, M; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Kristensen, SL; Køber, L; Langkilde, AM; Lindholm, D; Martinez, MFA; McMurray, JJV; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Shen, L; Sjöstrand, M; Solomon, SD | 1 |
| Bhatt, K; Brush, J; Civitello, A; Gordon, R; Jermyn, R; Jonsson, O; Kosiborod, MN; Lamba, S; Lampert, B; Nassif, ME; Pelzel, J; Qintar, M; Shavelle, DM; Tang, F; Windsor, SL | 1 |
| Bengtsson, O; Butt, JH; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Spertus, JA | 1 |
| Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Austin, B; Fong, MW; Hartupee, J; Husain, M; Inzucchi, SE; Khariton, Y; Kosiborod, MN; LaRue, SJ; Malik, AO; McGuire, DK; Nassif, ME; Ogunniyi, MO; Pitt, B; Scirica, BM; Tang, F; Umpierrez, G; Wenger, NK; Windsor, SL | 1 |
| Anand, IS; Bengtsson, O; Curtain, JP; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Akinci, B | 1 |
| Abe, M; Fujikawa, K; Fujita, Y; Fukunami, M; Furukawa, Y; Hata, M; Kawahira, M; Kawai, T; Kawasaki, M; Kayama, K; Kikuchi, A; Morita, T; Nakamura, J; Sanada, S; Seo, M; Shintani, A; Tamaki, S; Tanabe, K; Taniuchi, S; Umayahara, Y; Watanabe, T; Yamada, T; Yamamoto, K | 1 |
| Drożdż, J; Gackowski, A; Gumprecht, J; Jankowska, EA; Kaźmierczak, J; Kukulski, T; Lelonek, M; Leszek, P; Nessler, J; Ponikowski, P; Rozentryt, P; Rubiś, P; Siniarski, A; Witkowski, A | 1 |
| Adler, AI; Douch, E; Dunning, L; Elliott, N | 1 |
| da Silva, AA; do Carmo, JM; Hall, JE; Hall, ME; Li, J; Li, X; Lu, Q; Mouton, A; Omoto, ACM; Qiu, Y; Wang, Z | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Packer, M; Pocock, SJ; Sattar, N; Zannad, F | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Schueler, E; Steubl, D; Zannad, F | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Cai, Z; Cheng, H; Hu, X; Huang, H; Li, X; Liao, D; Tan, Z; Wang, C; Wang, Y; Wu, C; Wu, M; Xie, Y; Xu, F; Yin, K; Zeng, J; Zhao, W; Zhou, S; Zhou, X; Zhu, Y | 1 |
| Au Yeung, J; Khong, TK | 1 |
| Bengtsson, O; Butt, JH; Diez, M; Docherty, KF; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Ogunniyi, MO; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Bengtsson, O; Böhm, M; Chiang, CE; Desai, AS; Docherty, KF; Gasparyan, SB; Howlett, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Anyfanti, P; Sampani, E; Tsapas, A | 1 |
| Jensen, J; Møller, JE; Omar, M; Schou, M | 2 |
| Advani, A; Advani, SL; Batchu, SN; Connelly, KA; Kabir, G; Liu, Y; Siddiqi, FS; Yerra, VG | 1 |
| Beusekamp, JC; Boorsma, EM; Damman, K; Heerspink, HJL; Tromp, J; van der Meer, P; Voors, AA | 1 |
| Agbaje, OF; Coleman, R; George, JT; Grempler, R; Holman, RR; Hundertmark, MJ; Lamlum, H; Lee, J; Mahmod, M; Milton, JE; Neubauer, S; Niessen, HG; Rider, O; Rodgers, CT; Valkovič, L; Wicks, E | 1 |
| Chew, DS; Mark, DB | 1 |
| Goldhaber-Fiebert, JD; Heidenreich, PA; Khush, KK; Parizo, JT; Salomon, JA; Sandhu, AT; Spertus, JA | 1 |
| Claggett, B; de Boer, RA; DeMets, D; Hernandez, AF; Inzucchi, SE; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Öhrn, F; Petersson, M; Shah, SJ; Solomon, SD; Wilderäng, U | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Januzzi, JL; Packer, M; Pocock, SJ; Zannad, F | 1 |
| Santos-Gallego, CG; Van Spall, HGC | 1 |
| Faber, J; Forman, JL; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Schou, M; Tuxen, C | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Lam, CSP; Packer, M; Pfarr, E; Pocock, SJ; Sattar, N; Schnee, J; Sim, D; Tsutsui, H; Verma, S; Zannad, F | 1 |
| Cui, S; Dong, X; Gao, W; Liu, Y; Ren, L; Yin, X; Yu, L | 1 |
| Bayés-Genís, A; de la Espriella, R; Lorenzo, M; Miñana, G; Núñez, E; Núñez, G; Núñez, J; Santas, E | 1 |
| Lang, CC; Singh, JS; Struthers, AD | 1 |
| Jhund, PS; Lee, MMY; McMurray, JJV; Petrie, MC; Sattar, N | 1 |
| Borges, JI; Cora, N; Lymperopoulos, A; Sizova, A | 1 |
| Bellows, BK; Calvachi, P; Garan, AR; Gavin, MC; Hernandez, I; Isaza, N; Kazi, DS; Liu, CL; Raber, I; Shen, C | 1 |
| Bengtsson, O; Claggett, B; Docherty, KF; Ferreira, JP; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Atallah-Lajam, F; Badimon, JJ; Fuster, V; Giannarelli, C; Lala, A; Macaluso, F; Mancini, D; Requena-Ibáñez, JA; Rodriguez-Cordero, A; Santos-Gallego, CG; Sanz, J; Sartori, S; Vargas-Delgado, AP | 1 |
| Anker, SD; Asselbergs, F; Butler, J; Fitchett, D; Inzucchi, SE; Koudstaal, S; Lund, LH; Ofstad, AP; Savarese, G; Schrage, B; Uijl, A; Vedin, O; Wanner, C; Zannad, F; Zwiener, I | 1 |
| Chew, DP; Chong, W; De Pasquale, C; De Pasquale, CG; Hecker, T; Horsfall, M; Ilyas, F; Jones, L; Mangoni, AA; Selvanayagam, JB; Stranks, S; Swan, A; Tee, SL; Thomas, S; Wollaston, F | 1 |
| Abraham, WT; Anker, SD; Brueckmann, M; Hauske, S; Koitka-Weber, A; Lindenfeld, J; Peil, B; Pfarr, E; Ponikowski, P; Ritter, I; Salsali, A; Wanner, C | 1 |
| Ademi, Z; Kompa, AR; Liew, D; Owen, AJ; Savira, F; Tonkin, A; Wang, BH; Zomer, E; Zoungas, S | 1 |
| Asai, K; Hoshika, Y; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K | 1 |
| Carbone, S; daSilva-deAbreu, A; Lavie, CJ | 1 |
| Bhatt, DL; Cahn, A; Diaz, R; Gause-Nilsson, IAM; Goudev, A; Kuder, J; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Oyama, K; Park, KS; Raz, I; Sabatine, MS; Špinar, J; Wilding, JPH; Wiviott, SD | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Solomon, SD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Bengtsson, O; Curtain, JP; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Wanner, C; Zannad, F; Zeller, C | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure-Valenzuela, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Lam, CSP; Marx, N; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Sattar, N; Schnaidt, S; Schnee, JM; Senni, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zeller, C; Zhang, J | 1 |
| Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH | 1 |
| Brand-Arzamendi, K; Garg, A; Liu, X; Quan, A; Shi, X; Singh, KK; Verma, S; Wen, XY; Yun, J | 1 |
| Tschöpe, D | 1 |
| Arya, N; Birkeland, KI; Bodegård, J; Cavender, MA; Fenici, P; Fu, AZ; Hammar, N; Holl, RW; Jørgensen, ME; Khunti, K; Kosiborod, M; Norhammar, A; Thuresson, M; Wilding, JP | 1 |
| Lehrke, M; Marx, N | 2 |
| Chilton, RJ | 1 |
| Verbrugge, FH | 1 |
| Dietl, A; Maack, C | 1 |
| Martens, P; Mullens, W; Verbrugge, FH | 1 |
| Anker, SD; Butler, J; Filippatos, G; Packer, M; Zannad, F | 1 |
| Anker, SD; Bernstein, RA; Brueckmann, M; Butler, J; Cheung, AK; Filippatos, G; George, JT; Green, JB; Hamo, CE; Januzzi, JL; Kaul, S; Lam, CSP; Lip, GYH; Marx, N; McCullough, PA; Mehta, CR; Pocock, SJ; Ponikowski, P; Rosenstock, J; Salsali, A; Sattar, N; Scirica, BM; Shah, SJ; Tsutsui, H; Verma, S; Wanner, C; Woerle, HJ; Zannad, F | 1 |
| Chien, FJ; Eisen, HJ; Kim, DH | 1 |
| Paneni, F | 1 |
| Butler, J; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Helmlinger, G; McMurray, JJV | 1 |
| Baig, F; Choy, AM; Lang, CC; McCrimmon, RJ; Mordi, IR; Mordi, NA; Singh, JS; Struthers, AD | 1 |
| Bjornstad, P; Cherney, DZI; Lovshin, JA; Lytvyn, Y; Udell, JA | 1 |
| Dobashi, S; Fujii, T; Hashimoto, H; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 1 |
| Kitzman, DW; Packer, M | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Anzai, T; Asakura, M; Hamasaki, T; Hashimura, K; Imazu, M; Ito, S; Kitakaze, M; Mori, K; Watanabe, M; Yamamoto, H; Yasuda, S; Yasumura, Y; Yoshihara, F | 1 |
| Abbate, A; Billingsley, HE; Buckley, LF; Buzzetti, R; Canada, JM; Carbone, S; Christopher, S; Dixon, DL; Kadariya, D; Markley, R; Medina de Chazal, H; Trankle, CR; Van Tassell, BW; Vo, C | 1 |
| Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B | 1 |
| Bansilal, S; Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IA; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JP; Wiviott, SD | 1 |
| Kulikov, NV; Obrezan, AG | 1 |
| Marx, N; Wanner, C | 1 |
| Katsiki, N; Triposkiadis, F | 1 |
| Bengel, P; Bollenberg, H; Fischer, T; Gummert, J; Hamdani, N; Hasenfuss, G; Kovács, Á; Maier, LS; Mustroph, J; Pabel, S; Renner, A; Schach, C; Sossalla, S; Streckfuss-Bömeke, K; Tirilomis, P; Tschöpe, C; Van Linthout, S; Wagner, S | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Cannon, CP; Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Kaspers, S; McGuire, DK; Pfarr, E; Sambevski, S; Scirica, BM; Zinman, B | 1 |
| Abascal, V; Atallah-Lajam, F; Badimon, JJ; Contreras, JP; Fergus, I; Fuster, V; Garcia-Ropero, A; Lala, A; Mancini, D; Moreno, P; Pinney, SP; Santos-Gallego, CG; Sanz, J; Tamler, R | 1 |
| Araújo, I; Campos, L; Cunha, GJL; Fonseca, C; Gomes, RV; Mendes, G; Morais, R; Rocha, BML | 1 |
| Böhm, M; Brueckmann, M; Ferreira, JP; Fitchett, D; George, J; Januzzi, J; Kaul, S; Ofstad, AP; Petrie, MC; Wanner, C; Zannad, F; Zeller, C | 1 |
| Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Januzzi, J; Lund, LH; Ofstad, AP; Sattar, N; Savarese, G; Verma, S; Wanner, C; Zeller, C; Zinman, B | 1 |
| McMurray, JJV; Verma, S | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Desai, AS; Furtado, RHM; Gause-Nilsson, I; Goto, S; Johanson, P; Johansson, PA; Kato, ET; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Furtado, RHM; Gause-Nilsson, IAM; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Raz, I; Ruff, CT; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 2 |
| Chang, CY; Chen, WY; Chen, YF; Dai, ZK; Jhuang, WJ; Jhuo, SJ; Lee, AS; Lee, HC; Liu, PL; Shiou, YL | 1 |
| Bessette, LG; Brodovicz, KG; Déruaz-Luyet, A; Franklin, JM; Kulldorff, M; Najafzadeh, M; Patorno, E; Pawar, A; Sambevski, S; Santiago Ortiz, AJ; Schneeweiss, S | 1 |
| Badimon, JJ; Flores, E; Fuster, V; Garcia-Ropero, A; Hajjar, RJ; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; San Antonio, R; Santos-Gallego, CG; Sanz, J; Watanabe, S | 1 |
| Lehrke, M | 1 |
| Heerspink, HJL; Idzerda, NMA; Pena, MJ; Sjostrom, DC; Stefansson, BV; Wheeler, DC | 1 |
| de Boer, RA; Hillebrands, JL; Oberdorf-Maass, SU; Pavez Giani, MG; Schouten, EM; Silljé, HHW; van Goor, H; van Veldhuisen, DJ; Westenbrink, BD; Yurista, SR | 1 |
| Kondo, H; Takahashi, N | 1 |
| Bauersachs, J; Berliner, D | 1 |
| Polovina, MM; Seferović, JP; Seferović, PM | 1 |
| Brueckmann, M; Butler, J; Cheung, AK; Fitchett, D; George, J; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| Kosiborod, M; Lam, CSP; Verma, S | 1 |
| Abraham, WT; Anker, SD; Brueckmann, M; Brun, M; Jamal, W; Lindenfeld, J; Macesic, H; Peil, B; Ponikowski, P; Salsali, A; Ustyugova, A; Zeller, C | 1 |
| Bruun, NE; Fosbøl, E; Frederiksen, PH; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L | 1 |
| WOLLENBERGER, A | 1 |
| Kihara, Y; Nakano, Y; Sairaku, A | 1 |
| Ding, W; Dong, M; Liao, Y; Liu, J; Liu, S; Liu, Y; Wang, R; Yan, D; Zhang, Y; Zheng, N | 1 |
| Kırat, T; Köse, N | 1 |
| Dohi, K; Fujii, E; Fujimoto, N; Ito, M; Moriwaki, K; Nakamori, S; Omori, T; Sato, Y; Takeuchi, T; Yamada, N | 1 |
| Peters, MN; Pollock, JS; Rajagopalan, S | 1 |
| Scheen, AJ | 1 |
| Cherney, DZ; Lytvyn, Y; Rajasekeran, H | 1 |
| Einecke, D | 1 |
| Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A | 1 |
| Laubner, K; Seufert, J | 1 |
| Murín, J | 1 |
| Ceriello, A; Genovese, S; Gronda, E; Mannucci, E | 1 |
| Albuquerque Rocha, N; McGuire, DK; Neeland, IJ; Pham, D | 1 |
| Cherney, DZ; Udell, JA | 1 |
| Gause-Nilsson, I; Johnsson, E; Kosiborod, M; Sonesson, C; Xu, J | 1 |
| Bisping, E; Gasser, R; Grimm, M; Haas, T; Huber, MS; Pieske, B; Rainer, PP; Roessl, U; von Lewinski, D; Wasler, A; Wilhelm, B | 1 |
| MARTELLI, A | 1 |
| GALLINELLI, R | 1 |
| GOLAVSKII, VE | 1 |
| TELERMAN, M | 1 |
| LUSENA, M | 1 |
| ROTHLIN, E | 1 |
| MACREZ, C; MOUQUIN, M; PARIS, P; RENARD, J | 1 |
| Alfiero, R; Cocco, G; Padula, A; Rizzo, A; Strozzi, C; Tasini, MT; Urso, L | 1 |
| Dai, RH; Li, Y; Luo, HM | 1 |
43 review(s) available for glucose, (beta-d)-isomer and Cardiac Failure
| Article | Year |
|---|---|
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
[Practical approach of dapagliflozin for the treatment of heart failure. Role of primary care physician].
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Physicians, Primary Care; Stroke Volume; Ventricular Function, Left | 2021 |
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left | 2022 |
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Humans; Prospective Studies; Risk Assessment | 2022 |
Direct cardiac effects of SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Inflammation; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2023 |
Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review.
Topics: Aged; Benzhydryl Compounds; Dehydration; Diabetes Mellitus, Type 2; Glucosides; Heart Arrest; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Stroke Volume; Ventricular Function, Left | 2022 |
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Comprehensive review of SGLT2 inhibitors' efficacy through their diuretic mode of action in diabetic patients.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans; Observational Studies as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction: plain language summary of the EMPEROR-Reduced study.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Stroke Volume | 2023 |
CaMKII and GLUT1 in heart failure and the role of gliflozins.
Topics: Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Glucose Transporter Type 1; Glucosides; Heart Failure; Humans; Ketone Bodies; Myocardium; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Topics: Aged; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Body Mass Index; Case-Control Studies; Cause of Death; Clinical Trials as Topic; Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Patient Outcome Assessment; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Glucosides; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
SGLT2 inhibitors in people with and without T2DM.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
An update on dapagliflozin for the treatment of heart failure.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis | 2017 |
Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis | 2017 |
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetic Cardiomyopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.
Topics: Antioxidants; Benzhydryl Compounds; Calcium; Clonazepam; Glucosides; Heart Failure; Humans; Mitochondria, Heart; Oxidation-Reduction; Oxidative Stress; Ranolazine; Reactive Oxygen Species; Risk Factors; Thiazepines | 2017 |
SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.
Topics: Benzhydryl Compounds; Disease Progression; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Natriuresis; Sodium-Glucose Transporter 1 | 2017 |
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Pharmacologic Management for Heart Failure and Emerging Therapies.
Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan | 2017 |
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
[Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment].
Topics: Benzhydryl Compounds; Chronic Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
New drugs: big changes in conservative heart failure therapy?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Enzyme Activators; Glucosides; Heart Failure; Humans; Hyperkalemia; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Iron; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea | 2019 |
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss | 2016 |
[Are some antidiabetic drugs also drugs useful for heart failure treatment?].
Topics: Benzhydryl Compounds; Cardiotonic Agents; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Risk Factors | 2016 |
Glucagon and heart in type 2 diabetes: new perspectives.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Impact of empagliflozin in patients with diabetes and heart failure.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
[Old and new positive inotropic drugs: problems and controversies].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Glucagon; Glucosides; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Quinazolines; Xanthines | 1984 |
141 trial(s) available for glucose, (beta-d)-isomer and Cardiac Failure
| Article | Year |
|---|---|
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.
Topics: Aged; Benzhydryl Compounds; Female; Glucose; Glucosides; Heart Failure; Humans; Male; Middle Aged; Pulse Wave Analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prospective Studies; Stroke Volume; Transcatheter Aortic Valve Replacement; Treatment Outcome; Ventricular Function, Left | 2022 |
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Exercise; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires | 2021 |
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
Topics: Benzhydryl Compounds; Blood Volume; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Medicare; Myocardial Infarction; United States | 2022 |
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Topics: 3-Hydroxybutyric Acid; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Chronic Disease; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Up-Regulation; Vascular Stiffness | 2021 |
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Ventricular Function, Left | 2022 |
Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
Topics: Aged; Benzhydryl Compounds; Biological Specimen Banks; Diabetes Mellitus, Type 2; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Heart Failure; Heart Transplantation; Heart Ventricles; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left | 2022 |
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial.
Topics: Benzhydryl Compounds; Ethnicity; Glucosides; Heart Failure; Humans; Minority Groups; Quality of Life; Stroke Volume | 2022 |
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study.
Topics: Aged; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Thiophenes; Ventricular Function, Left | 2022 |
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2022 |
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Stroke Volume | 2022 |
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume; Treatment Outcome | 2022 |
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Ventricular Dysfunction, Left | 2022 |
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Frailty; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Topics: Acute Kidney Injury; Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucose; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters; Ventricular Dysfunction, Left | 2022 |
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2022 |
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
Topics: Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Pilot Projects; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss | 2022 |
Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.
Topics: Body Fluids; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Treatment Outcome | 2022 |
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Heart Failure; Humans; Hyperuricemia; Male; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2022 |
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans | 2022 |
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
Topics: Benzhydryl Compounds; Biomarkers; Ferritins; Glucosides; Heart Failure; Hepcidins; Humans; Iron; Iron Deficiencies; Receptors, Erythropoietin; Receptors, Transferrin; Stroke Volume; Transferrins | 2022 |
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Topics: Benzhydryl Compounds; Frailty; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2022 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Topics: Aged; Aged, 80 and over; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Positron Emission Tomography Computed Tomography; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Cardiomyopathies; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume; Uric Acid; Ventricular Function, Left | 2022 |
Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hypotension; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.
Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Calcium; Connexin 43; Disease Models, Animal; Fura-2; Glucose; Glucosides; Heart Failure; Monocrotaline; Pulmonary Arterial Hypertension; Rats; Sodium; Ventricular Dysfunction, Right; Ventricular Remodeling | 2022 |
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Topics: Aged; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume; Ventricular Function, Left | 2022 |
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Topics: Benzhydryl Compounds; Furosemide; Glucosides; Heart Failure; Humans | 2023 |
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Kidney; Male | 2023 |
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Function, Left | 2022 |
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
The win ratio method in heart failure trials: lessons learnt from EMPULSE.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2023 |
Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Plasma Volume; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2019 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebo Effect; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Ventricular Function, Left; Young Adult | 2020 |
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Odds Ratio; Placebo Effect; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Ventricular Function, Left | 2020 |
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Inpatients; Male; Registries; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2020 |
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Ketone Bodies; Length of Stay; Mortality; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Treatment Outcome | 2020 |
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Topics: Anhydrides; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sorbitol; Treatment Outcome | 2020 |
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Risk Factors; Thrombolytic Therapy | 2020 |
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Placebos; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2020 |
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged | 2020 |
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2020 |
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2; Stroke Volume; Ventricular Function, Left | 2020 |
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Europe; Glucosides; Heart Failure; Humans; North America; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2020 |
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume | 2020 |
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Topics: Accelerometry; Activities of Daily Living; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outcome Assessment, Health Care; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Glucosides; Heart Failure; Humans; Outpatients; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2020 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
Topics: Aged; Benzhydryl Compounds; Biomarkers; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2020 |
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiac Imaging Techniques; Double-Blind Method; Exercise Test; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Middle Aged; Sodium | 2021 |
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Cardiovascular Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Male; Pulmonary Disease, Chronic Obstructive; Stroke Volume | 2021 |
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Topics: Aged; Benzhydryl Compounds; Echocardiography; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Organ Size; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2021 |
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Pilot Projects; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure | 2021 |
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles | 2021 |
[Empagliflozin and heart failure: the EMPEROR-Reduced trial].
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Stroke Volume; Ventricular Function, Left | 2021 |
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Pulmonary Artery; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left | 2021 |
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left | 2021 |
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Lung; Quality of Life | 2021 |
Effect of dapagliflozin on anaemia in DAPA-HF.
Topics: Anemia; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume | 2021 |
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; COVID-19; Creatinine; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Glucosides; Heart Failure; Hospitalization; Humans; Japan; Kidney; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2021 |
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Blood Volume; Diabetes Mellitus, Type 2; Diuretics; Drug Synergism; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hematocrit; Humans; Male; Natriuretic Peptides; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Water-Electrolyte Imbalance | 2021 |
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
Topics: Aged; Benzhydryl Compounds; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Humans; Hyperkalemia; Kidney Function Tests; Male; Mineralocorticoid Receptor Antagonists; Outcome and Process Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Withholding Treatment | 2021 |
EMPEROR reduced - empagliflozin in patients with heart failure and reduced ejection fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients.
Topics: Anemia; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prospective Studies; Stroke Volume | 2022 |
Effect of dapagliflozin in patients with heart failure.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Topics: Aged; Benzhydryl Compounds; Disease Progression; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life | 2021 |
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Ventricular Function, Left | 2021 |
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.
Topics: Benzhydryl Compounds; Biomarkers; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume; Troponin T | 2021 |
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
Topics: Benzhydryl Compounds; Double-Blind Method; Glucosides; Heart Failure; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Topics: Benzhydryl Compounds; Ethnicity; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Topics: Aged; Benzhydryl Compounds; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Survival Rate; Time Factors; Ventricular Function, Left | 2021 |
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tropism | 2021 |
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Prognosis; Risk Factors; Stroke Volume | 2021 |
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial.
Topics: Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2021 |
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Myocardial Infarction; Prospective Studies; Water-Electrolyte Balance | 2022 |
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic | 2021 |
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
Topics: Arrhythmias, Cardiac; Benzhydryl Compounds; Death, Sudden; Death, Sudden, Cardiac; Glucosides; Heart Arrest; Heart Failure; Humans; Male; Stroke Volume; Ventricular Function, Left | 2021 |
Empagliflozin and Major Renal Outcomes in Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Germany; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Internationality; Male; Middle Aged; Mortality; Norway; Registries; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Treatment Outcome; United Kingdom; United States | 2017 |
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Topics: Adult; Benzhydryl Compounds; Blood Volume; Bumetanide; Diuresis; Diuretics; Drug Combinations; Drug Interactions; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Osmolar Concentration; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Water-Electrolyte Imbalance; Young Adult | 2018 |
Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Chronic Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Scotland; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.
Topics: Benzhydryl Compounds; Body Mass Index; Cardiorespiratory Fitness; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Drug Interactions; Female; Glucosides; Heart; Heart Failure; Humans; Male; Middle Aged; Obesity; Oxygen Consumption; Pilot Projects; Respiratory System; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2018 |
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Coronary Artery Bypass; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Risk; Treatment Outcome | 2018 |
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Topics: Aged; Benzhydryl Compounds; Cerebral Infarction; Diabetes Mellitus, Type 2; Diuresis; Drug Monitoring; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Cause of Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Topics: Benzhydryl Compounds; Cardiovascular Agents; Double-Blind Method; Exercise Tolerance; Glucosides; Heart Failure; Humans; Magnetic Resonance Imaging; New York City; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Function, Right; Walk Test | 2019 |
Empagliflozin Targeting the Real-World Heart Failure Population.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus; Drug Delivery Systems; Female; Follow-Up Studies; Glucosides; Heart Failure; Humans; Male; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cause of Death; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Topics: Aged; Benzhydryl Compounds; Brain Ischemia; Cause of Death; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Time Factors; Treatment Outcome | 2019 |
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Exercise Tolerance; Female; Glucosides; Heart Failure; Humans; Male; Patient Reported Outcome Measures; Physical Functional Performance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prediabetic State; Reference Values; Registries; Treatment Outcome | 2019 |
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds | 2016 |
[Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure].
Topics: Adolescent; Adult; Aged; Astragalus propinquus; Cardiotonic Agents; Drugs, Chinese Herbal; Female; Gated Blood-Pool Imaging; Glucosides; Heart Failure; Humans; Injections, Intravenous; Male; Middle Aged; Saponins; Single-Blind Method; Triterpenes; Ventricular Function, Left | 1995 |
282 other study(ies) available for glucose, (beta-d)-isomer and Cardiac Failure
| Article | Year |
|---|---|
Teasing the Immune System to Repair the Heart.
Topics: Animals; Cell- and Tissue-Based Therapy; Disease Models, Animal; Heart Failure; Immune System; Leukocytes, Mononuclear; Mesenchymal Stem Cell Transplantation; Mice; Reperfusion Injury; Zymosan | 2020 |
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Philippines; Stroke Volume | 2021 |
Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Pressure; Cardiotonic Agents; Disease Management; Disease Models, Animal; Gene Expression Profiling; Glucosides; Heart Failure; Immunohistochemistry; Metabolome; Metabolomics; Mice; Microcirculation; Models, Biological; Norepinephrine; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left | 2021 |
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Current Role of Dapagliflozin in Clinical Practice.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Study Projects Lifetime Benefits of Dapagliflozin in HFrEF.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Cause of Death; Clinical Trials, Phase III as Topic; Glucosides; Heart Failure; Humans; Life Expectancy; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume | 2021 |
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Sodium-Glucose Transporter 2 | 2022 |
Eligibility for SGLT2 Inhibitors in Heart Failure Without the Race Coefficient for Kidney Function Estimation.
Topics: Aged; Benzhydryl Compounds; Black or African American; Eligibility Determination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2021 |
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia.
Topics: Benzhydryl Compounds; Colombia; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
Topics: Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Muscles; Natriuretic Peptide, Brain; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2021 |
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors.
Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Death, Sudden; Glucose; Glucosides; Heart Arrest; Heart Failure; Humans; Sodium; Stroke Volume; Ticks | 2022 |
[Dapagliflozin in the prevention and treatment of heart failure].
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume; Ventricular Function, Left | 2021 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Topics: Aged; Atrial Fibrillation; Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left | 2021 |
Dapagliflozin improves exercise capacity in HFpEF.
Topics: Benzhydryl Compounds; Exercise Tolerance; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Hospitalization; Humans; Insulins; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Metabolic Diseases; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Glucose; Glucosides; Heart Failure; Mice; Sirtuin 1 | 2022 |
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Hypotension; Male; Stroke Volume | 2022 |
In HFpEF, adding empagliflozin to usual care reduced a composite of CV death or HF hospitalization at a median 26 mo.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume | 2022 |
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes.
Topics: Diabetes Mellitus, Type 2; Digoxin; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzhydryl Compounds; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Risk Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2022 |
Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2022 |
SGLT2 inhibitors may prevent diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Reply to: Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2022 |
Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2022 |
SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Heart Failure; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cardiovascular Benefits of Digoxin and Empagliflozin in Patients with Chronic Heart Failure: The DIG Trial Revisited.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Glucosides; Heart Failure; Humans | 2022 |
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection f
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters | 2022 |
Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemia; Ketosis | 2022 |
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Insulins; Metformin; Prospective Studies; Stroke Volume | 2022 |
SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitor-Mediated Blunting of Blood Volume Redistribution: A Candidate Mechanism for Attenuating Cardiac Filling Pressures and Exercise Intolerance in Heart Failure-How Do the Data Stack up?
Topics: Benzhydryl Compounds; Blood Volume; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 | 2022 |
Benefit of empagliflozin in acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2022 |
Empagliflozin Reverses Late Na
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Heart Failure; Humans; Mice; Myocytes, Cardiac; Stroke Volume | 2022 |
FDA Expands Empagliflozin Heart Failure Indication.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; United States | 2022 |
Empagliflozin Reduces Hospitalization for Heart Failure With Preserved Ejection Fraction, but Not Mortality Outcomes.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume | 2022 |
Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial".
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
In brief: Expanded heart failure indication for empagliflozin (Jardiance).
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2022 |
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin Improves Quality of Life in HFpEF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2022 |
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyponatremia; Sodium; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2022 |
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiomyopathies; Fatty Acids; Female; Glucosides; Heart Failure; Humans; Ketones; Ketosis; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin Safe and Effective for Heart Failure With Frailty.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Frailty; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2022 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyperkalemia; Potassium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Glucosides; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Potassium; Stroke Volume; Ventricular Function, Left | 2022 |
Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure: Is Age Just a Number?
Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume | 2022 |
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Thailand | 2022 |
Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue-molecules and SGLT2i dapagliflozin.
Topics: Adipose Tissue; Benzhydryl Compounds; Endothelial Cells; Female; Glucosides; Heart Failure; Humans; Neutrophils; Obesity; Phenotype; Stroke Volume | 2022 |
Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Heart Ventricles; Humans; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2022 |
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Prediabetic State; Stroke Volume | 2022 |
What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
[Empagliflozin in the treatment of heart failure with preserved ejection fraction].
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Liquiritin inhibits H
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Antioxidants; Catalase; Flavanones; Glucosides; Glutathione; Glutathione Reductase; Heart Failure; Humans; Hydrogen Peroxide; Interleukin-1beta; Interleukin-6; Lactate Dehydrogenases; Molecular Docking Simulation; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Sirtuin 1; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2022 |
Empagliflozin in patients hospitalized for acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Uric Acid | 2022 |
Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure Trial.
Topics: Benzhydryl Compounds; Biomarkers; Clinical Trials as Topic; Glucosides; Heart Failure; Humans | 2022 |
Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Glucosides; Heart Failure; Male; Mice; Mitochondria; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin for patients with heart failure and reduced ejection fraction.
Topics: Adult; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure.
Topics: Glucosides; Heart Failure; Humans; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis | 2022 |
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Echocardiography; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Stroke Volume | 2022 |
Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients.
Topics: Benzhydryl Compounds; C-Reactive Protein; Cardiomyopathies; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Heart Failure; Humans; Interleukin-6; Tumor Necrosis Factor-alpha | 2022 |
Dapagliflozin improves outcomes in HFmrEF and HFpEF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume; Ventricular Function, Left | 2022 |
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Percutaneous Coronary Intervention; Prognosis; Receptors, Angiotensin; Retrospective Studies; Triglycerides | 2022 |
Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hypoglycemic Agents; Mice; Stroke Volume | 2022 |
Response to Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin.
Topics: Animals; B-Lymphocytes; Benzhydryl Compounds; Bone Marrow; Glucosides; Heart Failure; Immunoglobulin D; Immunoglobulin M; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Percutaneous Coronary Intervention; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Remodeling | 2022 |
How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases.
Topics: Adolescent; Benzhydryl Compounds; Delivery of Health Care; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; State Medicine; Stroke Volume | 2023 |
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin Inhibits Ventricular Remodeling in Heart Failure Rats by Activating Autophagy through AMPK/mTOR Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Atrial Natriuretic Factor; Autophagy; Autophagy-Related Proteins; Benzhydryl Compounds; Caspase 3; Glucosides; Heart Failure; Hypoxia; Myocytes, Cardiac; Rats; Signal Transduction; TOR Serine-Threonine Kinases; Ventricular Remodeling | 2022 |
The position of SGLT2 inhibitors in current medical practice - update 2022.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Drinking Water; Glucose; Glucosides; Heart Failure; Lipids; Muscle, Skeletal; Obesity; Rats; Saponins; Sodium; Stroke Volume; Ventricular Function, Left | 2022 |
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
SGLT2 inhibitors in heart failure: insights from plasma proteomics.
Topics: Glucosides; Heart Failure; Humans; Proteomics; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; White | 2023 |
The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus.
Topics: Arrhythmias, Cardiac; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male | 2023 |
Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2023 |
Empagliflozin benefits in patients with heart failure and preserved ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF).
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2023 |
Is Dapagliflozin a Cardiac Anti-Aging Drug?
Topics: Aging; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2023 |
Trace element equilibrium in acute heart failure and the effect of empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Trace Elements | 2023 |
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Proportional Hazards Models; Stroke Volume | 2023 |
Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left | 2023 |
Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2023 |
Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
Topics: Benzhydryl Compounds; Frailty; Glucosides; Heart Failure; Humans | 2023 |
Using dapagliflozin in patients with heart failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2023 |
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Heart Failure, Diastolic; Hospitalization; Humans; Male; Medicare; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2023 |
In brief: Expanded heart failure indication for dapagliflozin (Farxiga).
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume | 2023 |
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2023 |
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Topics: Benzhydryl Compounds; Cohort Studies; Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Topping Off the Pill Box: Dapagliflozin, Heart Failure, and Polypharmacy.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Polypharmacy; Stroke Volume; Ventricular Function, Left | 2023 |
In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputations.
Topics: Amputation, Surgical; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Meta-Analysis as Topic | 2023 |
Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Stroke Volume | 2023 |
Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice.
Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Homeostasis; Humans; Mice; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2023 |
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Topics: Animals; Aorta; Benzhydryl Compounds; Biomarkers; Blood Pressure; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cytokines; Disease Models, Animal; Female; Fibrosis; Glucosides; Heart Failure; Hypertension; Inflammation Mediators; Lipids; Nitric Oxide; Norepinephrine; Sodium-Glucose Transporter 2 Inhibitors; Sus scrofa; Sympathetic Nervous System; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Heart-Failure Therapy - New Drugs but Old Habits?
Topics: Benzhydryl Compounds; Glucosides; Habits; Heart Failure; Humans; Stroke Volume | 2019 |
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2019 |
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
SGLT-2 inhibitors in heart failure: a new therapeutic avenue.
Topics: Benzhydryl Compounds; Death, Sudden, Cardiac; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Building the Foundation for a New Era of Quadruple Therapy in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Disease Models, Animal; Fatty Acids; Glucosides; Heart Failure; Insulin; Male; Mice; Mice, Inbred C57BL; Mitochondria; Muscle Strength; Muscle, Skeletal; Oxidation-Reduction; Oxidative Phosphorylation; Physical Conditioning, Animal; Physical Endurance; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin in heart failure: new frontiers.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2019 |
Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.
Topics: Animals; Fibrosis; Gene Expression Regulation; Glucosides; Heart Failure; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Pyrazoles; RNA, Messenger; Sodium-Glucose Transporter 1; Ventricular Remodeling | 2020 |
Dapagliflozin for HFrEF - improved outcomes across all ages.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiology; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Europe; Glucagon-Like Peptide-1 Receptor; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2020 |
The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
Topics: Benzhydryl Compounds; Disease Progression; Glucosides; Heart Failure; Humans; Incidence; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Japan; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2020 |
Topics: Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Heart Failure; Humans; Male; Mortality; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2020 |
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Topics: Animals; Benzhydryl Compounds; Carrier Proteins; Glucosides; Heart Diseases; Heart Failure; Inflammasomes; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Nucleotides; Stroke Volume | 2020 |
Dapagliflozin Cut Risk of Worsening Heart Failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Topics: Animals; Benzhydryl Compounds; Calcium Signaling; Disease Models, Animal; Glucosides; Heart Failure; Myocardial Infarction; Myocardium; Rats, Inbred F344; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left; Ventricular Pressure | 2020 |
Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
Topics: Benzhydryl Compounds; Double-Blind Method; Glucose; Glucosides; Heart Failure; Humans; Pilot Projects; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2020 |
Dapagliflozin in patients with heart failure and reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions.
Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
A Novel Cardioprotective Therapy That Also Improves Glycemia.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Glucosides; Heart Failure; Humans | 2020 |
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
Topics: Angiotensin Receptor Antagonists; Benzhydryl Compounds; Diuretics; Glucosides; Heart Failure; Humans | 2020 |
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuresis; Natriuretic Agents; Prospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
[Sodium glucose co-transporter 2 inhibitors in heart failure therapy].
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diastole; Diuresis; Female; Glucosides; Glycosuria; Heart Failure; Heart Ventricles; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Myocardium; Natriuresis; Physical Endurance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Walk Test | 2020 |
Prognosis of patients eligible for dapagliflozin in acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzhydryl Compounds; Cause of Death; Cohort Studies; Eligibility Determination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Patient Readmission; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Motivation; Sodium-Glucose Transporter 2 Inhibitors; Standard of Care; Stroke Volume | 2020 |
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Mortality; Sodium-Glucose Transporter 2 Inhibitors; Treatment Failure; Treatment Outcome | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Exercise Tolerance; Fosinopril; Glucosides; Heart Failure; Male; Myocardial Infarction; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Topics: Aged; Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Cyclic GMP-Dependent Protein Kinase Type I; Disease Models, Animal; Endothelial Cells; Female; Glucosides; Heart Failure; Humans; Inflammation Mediators; Male; Middle Aged; Myocytes, Cardiac; Oxidative Stress; Rats, Zucker; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2021 |
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
[Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2020 |
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Topics: Adult; Aged; Benzhydryl Compounds; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Female; Glucosides; Heart Failure; Hospital Costs; Humans; Incidence; Male; Middle Aged; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Myocytes, Cardiac; Oxidative Stress; Protein Kinases; Stroke Volume | 2021 |
SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers, Pharmacological; Drugs, Investigational; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States | 2020 |
Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy.
Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Myocardial Infarction; Myocardium; Sodium-Glucose Transporter 2 Inhibitors; Swine; Ventricular Function, Left | 2020 |
Dapagliflozin (Farxiga) - a new indication for heart failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Female; Germany; Glucosides; Heart Failure; Humans; Male; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Spain; Ventricular Function, Left | 2020 |
Dapagliflozin for heart failure: is it a class effect?
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Quadruple Therapy Is the New Standard of Care for HFrEF.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Standard of Care; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume; Thailand; Ventricular Function, Left | 2021 |
Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis.
Topics: Benzhydryl Compounds; Cardiomegaly; Extracellular Fluid; Glucosides; Heart; Heart Failure; Hemodynamics; Humans; Kidney; Models, Cardiovascular; Myocytes, Cardiac; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Pharmacology Focus: Dapagliflozin Use in Reduced Ejection Fraction Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
Topics: Animals; Benzhydryl Compounds; C-Peptide; Cardiotonic Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Heart Failure; Humans; Hyperinsulinism; Hypertension; Male; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left | 2020 |
Antihyperglycemic Drug Approved to Treat Heart Failure.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Stroke Volume; United States; United States Food and Drug Administration | 2020 |
More Evidence for SGLT2 Inhibitors in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Remodeling | 2020 |
The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Heart Failure; Humans | 2020 |
Empagliflozin improves outcomes in HFrEF regardless of diabetic status.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.
Topics: Animals; Benzhydryl Compounds; Biopsy; Cell Survival; Cellular Senescence; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucosides; Heart; Heart Failure; Inflammation; Male; Mice; Mice, Inbred C57BL; Myocardium; Sodium-Glucose Transporter 2; Stromal Cells; Ventricular Function, Left | 2020 |
Evaluation of dapagliflozin in the treatment of heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Volume; Computer Simulation; Diabetes Mellitus, Type 2; Diuresis; Glomerular Filtration Barrier; Glucosides; Heart Failure; Hematocrit; Hemodynamics; Humans; Models, Theoretical; Natriuresis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Remodeling | 2021 |
Current and Emerging Issues in the Management of Heart Failure in Primary Care.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Softening the Stiff Heart: SGLT2 Inhibition and Diastolic Function.
Topics: Benzhydryl Compounds; Fibrosis; Glucosides; Heart Failure; Humans; Predictive Value of Tests; Sodium-Glucose Transporter 2 | 2021 |
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
Topics: Animals; Benzhydryl Compounds; Diastole; Fibrosis; Glucosides; Heart Failure; Heart Ventricles; Predictive Value of Tests; Stroke Volume; Swine; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Organ protection beyond glycaemic control with SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Glucosides; Glycemic Control; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2020 |
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans | 2020 |
Understanding the Mechanistic Benefit of Heart Failure Drugs Matters.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Pharmaceutical Preparations; Stroke Volume | 2020 |
When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Incidence; Stroke Volume | 2021 |
SGLT2 inhibitors: expanding their Empire beyond diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
EMPEROR-REDUCED reigns while EMPERIAL whimpers.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
Topics: Benzhydryl Compounds; Diuretics, Osmotic; Glucosides; Heart Failure; Humans; Sodium | 2021 |
Highlights from the European society of cardiology congress 2020.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Clinical Trials as Topic; Colchicine; Coronary Artery Disease; Europe; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors; Tubulin Modulators; Uracil | 2021 |
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2021 |
Empagliflozin (Jardiance) for heart failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Heart failure drug treatment: the fantastic four.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Neprilysin; Pharmaceutical Preparations | 2021 |
Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
Topics: Diabetes Mellitus, Type 2; Diamond; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin in Heart Failure. Reply.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2021 |
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia, Eastern; Benzhydryl Compounds; Data Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Risk; Treatment Outcome; Young Adult | 2021 |
Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Patient-Centered Care; Quality of Life | 2021 |
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Expert Testimony; Female; Glucosides; Heart Failure; Humans; Male; Poland; Quality of Life; Stroke Volume; Ventricular Function, Left | 2021 |
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Health Policy; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; United Kingdom | 2021 |
Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Disease Models, Animal; Echocardiography; Glucosides; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardium; Oxidative Phosphorylation; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2021 |
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Fluid volume regulation in patients with heart failure.
Topics: Benzhydryl Compounds; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume | 2021 |
Fluid volume regulation in patients with heart failure.
Topics: Benzhydryl Compounds; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume | 2021 |
Fluid volume regulation in patients with heart failure - Authors' reply.
Topics: Benzhydryl Compounds; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume | 2021 |
Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Hypertrophy, Left Ventricular; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Sodium-Glucose Transporter 2; TWEAK Receptor; Ventricular Remodeling | 2022 |
Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Potassium; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial".
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Primary Prevention; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Stroke Volume | 2021 |
Efficacy and safety of dapagliflozin in the treatment of chronic heart failure: A protocol for systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Meta-Analysis as Topic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Treatment Outcome | 2021 |
Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies | 2021 |
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume | 2021 |
Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume | 2021 |
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.
Topics: Adrenal Glands; Animals; Benzhydryl Compounds; Cardiovascular Agents; Catecholamines; Glucosides; Heart Failure; Humans; Ketone Bodies; Models, Biological; Receptors, G-Protein-Coupled; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Structure-Activity Relationship; Sympatholytics | 2021 |
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires | 2021 |
Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection?
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Myocardium | 2021 |
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Is Dapagliflozin Cost-effective for Treating Heart Failure?
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Kidney | 2021 |
Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective.
Topics: Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Glucosides; Heart Failure; Humans | 2021 |
The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Heart Failure, Systolic; Humans; Obesity; Prognosis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2021 |
Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2021 |
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left | 2017 |
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
Topics: Animals; Animals, Genetically Modified; Aristolochic Acids; Benzhydryl Compounds; Biomarkers; Clinical Trials as Topic; Disease Models, Animal; Female; Glucosides; Heart Failure; Humans; Male; Zebrafish | 2017 |
Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus - Is it empaglifozin or the class?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Introduction.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2017 |
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Topics: Benzhydryl Compounds; Blood Vessels; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Kidney Tubules, Proximal; Myocardium; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchangers | 2017 |
Empagliflozin across the stages of diabetic heart disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans | 2018 |
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.
Topics: Aged, 80 and over; Body Weight; Glucosides; Heart Failure; Hospitalization; Humans; Male; Myocardial Perfusion Imaging; Sympathetic Nervous System; Thiophenes; Treatment Outcome | 2018 |
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Resistance; Glucosides; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Water-Electrolyte Balance | 2019 |
Empagliflozin directly improves diastolic function in human heart failure.
Topics: Animals; Benzhydryl Compounds; Biopsy; Diastole; Disease Models, Animal; Echocardiography; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Mice; Middle Aged; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Rats; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2018 |
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Topics: Benzhydryl Compounds; Cause of Death; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Topics: Animals; Atrial Function, Left; Atrial Natriuretic Factor; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fibrosis; Gene Expression Regulation; Glucosides; Heart Failure; Hemodynamics; Hypertension; Male; Myocardium; Natriuretic Peptide, Brain; Rats, Inbred SHR; Rats, Inbred WKY; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Stratifying the effects of SGLT2i.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Topics: Aged; Benzhydryl Compounds; Comparative Effectiveness Research; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; United States | 2019 |
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Topics: Analysis of Variance; Animals; Benzhydryl Compounds; Diabetes Mellitus; Disease Models, Animal; Echocardiography, Three-Dimensional; Glucosides; Heart Failure; Heart Function Tests; Random Allocation; Reference Values; Sodium-Glucose Transporter 2 Inhibitors; Statistics, Nonparametric; Stroke Volume; Swine; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2019 |
SGLT2 Inhibition: Changing What Fuels the Heart.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Ventricular Remodeling | 2019 |
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Topics: Animals; Benzhydryl Compounds; Echocardiography; Energy Metabolism; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left | 2019 |
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin and Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans | 2019 |
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Topics: Benzhydryl Compounds; Blood Volume; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics; Glucose; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Multicenter Studies as Topic; Myocardial Infarction; Natriuresis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Stroke; Stroke Volume | 2019 |
The energy metabolism of the failing heart and the metabolic action of the cardiac glycosides.
Topics: Cardiac Glycosides; Energy Metabolism; Glucosides; Heart; Heart Failure; Humans | 1949 |
Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure.
Topics: Diabetes Mellitus; Diuresis; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Thiophenes | 2015 |
Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models.
Topics: Adrenergic alpha-1 Receptor Agonists; Animals; Animals, Newborn; Atrial Natriuretic Factor; Cardiomegaly; Cardiotonic Agents; Cell Size; Cells, Cultured; Disease Models, Animal; Drugs, Chinese Herbal; Glucosides; Heart Failure; Heart Ventricles; Male; Mice, Inbred C57BL; Oxidative Stress; Phenylephrine; Rats; rho-Associated Kinases; Stilbenes; Ventricular Remodeling | 2015 |
Response to the letter by Akinori Sairaku et al.: Different mechanisms = synergic effect.
Topics: Diuresis; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Stroke Volume; Thiophenes | 2015 |
Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis | 2016 |
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2015 |
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Natriuresis; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
[Empagliflozin reduces heart failure risk by a third].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Heart Failure; Humans; Outcome Assessment, Health Care; Risk; Survival Rate | 2015 |
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
Topics: Benzhydryl Compounds; Cardiologists; Clinical Decision-Making; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Patient Selection; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics, Osmotic; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Longitudinal Studies; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sodium-Glucose Transport Proteins | 2017 |
Functional effects of glucose transporters in human ventricular myocardium.
Topics: Aged; Carbonates; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Glucose Transporter Type 1; Glucose Transporter Type 4; Glucosides; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Inhibitory Concentration 50; Insulin; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Myocardium; Phosphoinositide-3 Kinase Inhibitors; RNA, Messenger; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
[The use of Convallaria glucosides in the therapy of myocardial decompensation].
Topics: Convallaria; Glucosides; Heart Failure | 1953 |
[New associations of digitalis (d.purpurea) glucosides].
Topics: Digitalis; Digitalis Glycosides; Glucosides; Heart Failure; Humans; Plant Extracts | 1954 |
[Practical aspects of glucoside therapy in cardiac insufficiency].
Topics: Cardiac Glycosides; Glucosides; Heart Failure; Humans | 1957 |
[INFLUENCE OF CARDIOTONIC GLUCOSIDES ON THE INTERMEDIATE METABOLISM OF THE MYOCARDIUM].
Topics: Adenosine Triphosphatases; Cardiotonic Agents; Digitalis Glycosides; Glucosides; Heart Failure; Humans; Metabolism; Myocardium; Phosphates; Proteins | 1963 |
[Allergy to k-strophanthoside and other cardiokinetic glucosides; considerations on the dangers of intolerance of allergic types to drugs in general].
Topics: Glucosides; Heart Failure; Hypersensitivity; Immune System Diseases; Strophanthins | 1954 |
[Therapy of heart failure with digitalis glucosides].
Topics: Digitalis; Digitalis Glycosides; Glucosides; Heart Failure; Plant Extracts | 1950 |
[Therapeutic value of a glucoside extracted from oleander].
Topics: Glucosides; Heart Failure; Humans; Nerium | 1950 |